Precigen Unveils 'First-and-Only' PAPZIMEOS™ (zopapogene imadenovec-drba) for the Treatment of Recurrent Respiratory Papillomatosis (RRP)
Precigen has introduced PAPZIMEOS™ (zopapogene imadenovec-drba) as the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and potentially life-threatening disease of the respiratory tract caused by chronic HPV 6 or HPV 11 infection.
PAPZIMEOS™ is a non-replicating adenoviral vector-based immunotherapy designed to target the underlying cause of recurrent respiratory papillomatosis (RRP) by generating an immune response against HPV types 6 and 11. The therapy is administered through four subcutaneous injections over 12 weeks.
Symptoms of RRP include severe voice disturbance, breathing difficulties, and recurrent respiratory infections, with some patients requiring hundreds of surgeries over their lifetime. The disease carries a risk of airway obstruction, post-obstructive pneumonia, and, in rare cases, progression to cancer.
Recurrent respiratory papillomatosis (RRP) is a rare and chronic disease of the airways caused by human papillomavirus (HPV) types 6 and 11. It leads to the growth of benign tumours in the respiratory tract, resulting in voice changes, breathing difficulties, and recurrent infections. Patients often require repeated surgeries to manage the condition, sometimes hundreds over a lifetime.
PAPZIMEOS™ is the 'first-and-only' FDA-approved treatment for recurrent respiratory papillomatosis (RRP), offering a targeted option that addresses the underlying cause of this chronic and potentially life-threatening disease.
